Ultragenyx's rhGUS meets Phase III endpoint

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said rhGUS (UX003) met the primary endpoint in a Phase III study to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) by significantly reducing urinary excretion of glycosaminoglycan (GAG) dermatan sulfate

Read the full 340 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE